文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌中预测顺铂为基础新辅助化疗反应的基因组生物标志物评估

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
PubMed 文献 · Eur Urol · 2022-08-11

本研究在165例接受顺铂为基础新辅助化疗(NAC)后行根治性手术的肌层浸润性膀胱癌(MIBC)患者的独立回顾性队列治疗前经尿道电切标本中验证既往报道的基因组生物标志物。ERCC2有害突变与病理反应相关(应答者9/68 vs 非应答者2/95,p=0.009;FDR=0.03),而ERBB2、ATM、RB1、FANCC单独或联合改变与反应无相关性,上述标志物与病理完全缓解(ypT0N0)也无进一步关联。结论为ERCC2有害突变与NAC病理反应正相关,但与总生存或无复发生存无关,其他既往报道的标志物未获验证。

要点

  • ERCC2有害突变见于13%(9/68)可评估应答者和2%(2/95)可评估非应答者(p=0.009;FDR=0.03)。
  • ERBB2、ATM、RB1、FANCC单独或联合改变与NAC反应无相关性。
  • 上述生物标志物与病理完全缓解(ypT0N0)无进一步关联。

核心结论

  • ERCC2有害突变与NAC病理反应呈正相关,但与总生存或无复发生存无关。
  • 其他既往报道的基因组生物标志物未获验证。

研究设计与样本

  • 在165例MIBC患者的独立回顾性队列中,于NAC前经尿道电切标本中验证既往报道的基因组生物标志物。
  • 患者随后接受NAC和根治性手术,术后ypT0/Tis/Ta/T1N0定义为应答者。

主要发现

  • ERCC2有害突变见于9/68(13%)可评估应答者和2/95(2%)可评估非应答者(p=0.009;FDR=0.03)。
  • ERBB2改变与反应无相关性。
  • ATM、RB1、FANCC单独或联合改变与反应无相关性。
  • 探索性分析未发现其他基因组改变可区分NAC应答者与非应答者。
  • 上述生物标志物与术后病理完全缓解(ypT0N0)无进一步关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in ERBB2, and alterations in ATM, RB1, and FANCC are correlated with pathological response to NAC in MIBC. The objective of this study was to validate these genomic biomarkers in pretreatment transurethral resection material from an independent retrospective cohort of 165 patients with MIBC who subsequently underwent NAC and radical surgery. Patients with ypT0/Tis/Ta/T1N0 disease after surgery were defined as responders. Somatic deleterious mutations in ERCC2 were found in nine of 68 (13%) evaluable responders and two of 95 (2%) evaluable nonresponders (p = 0.009; FDR = 0.03). No correlation was observed between response and alterations in ERBB2 or in ATM, RB1, or FANCC alone or in combination. In an exploratory analysis, no additional genomic alterations discriminated between responders and nonresponders to NAC. No further associations were identified between the aforementioned biomarkers and pathological complete response (ypT0N0) after surgery. In conclusion, we observed a positive association between deleterious mutations in ERCC2 and pathological response to NAC, but not overall survival or recurrence-free survival. Other previously reported genomic biomarkers were not validated. PATIENT SUMMARY: It is currently unknown which patients will respond to chemotherapy before definitive surgery for bladder cancer. Previous studies described several gene mutations in bladder cancer that correlated with chemotherapy response. This study confirmed that patients with bladder cancer with a mutation in the ERCC2 gene often respond to chemotherapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gil-Jimenez A, van Dorp J, Contreras-Sanz A, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2022. PMID: 35965206. doi:10.1016/j.eururo.2022.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。